Loading...
XHKG0954
Market cap27mUSD
Dec 23, Last price  
0.40HKD
1D
0.00%
1Q
-13.04%
Jan 2017
-64.29%
Name

Changmao Biochemical Engineering Co Ltd

Chart & Performance

D1W1MN
XHKG:0954 chart
P/E
—
P/S
0.32
EPS
—
Div Yield, %
19.73%
Shrs. gr., 5y
—
Rev. gr., 5y
-0.06%
Revenues
637m
-12.73%
95,228,10693,041,986321,440,000397,420,000418,426,000385,302,000515,574,000620,233,000653,218,000703,032,000561,669,000514,779,000594,402,000630,841,000639,120,000494,580,000444,106,000547,976,000730,034,000637,078,000
Net income
-86m
L
46,525,46834,973,36967,358,00034,648,00045,929,00043,203,00075,773,00041,105,00049,455,00069,992,00037,223,00045,274,00033,172,0003,382,00050,525,00058,299,00016,827,00058,318,00081,423,000-86,057,000
CFO
-2m
L
16,424,16425,519,58863,716,00019,802,00074,378,00087,674,00057,081,00044,543,00093,619,00068,584,00097,393,00071,919,00049,132,00065,781,00044,478,000118,327,00058,905,000-6,939,00019,633,000-2,349,000
Dividend
May 22, 20230.086829 HKD/sh
Earnings
Mar 24, 2025

Profile

Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. The company is also involved in the research and development of medicine and nutraceutical products; production and sale of food additives; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.
URL
https://www.cmbec.com/
IPO date
Jun 28, 2002
Employees
574
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
637,078
-12.73%
730,034
33.22%
547,976
23.39%
Cost of revenue
694,576
660,089
603,641
Unusual Expense (Income)
NOPBT
(57,498)
69,945
(55,665)
NOPBT Margin
9.58%
Operating Taxes
27,938
6,286
26,202
Tax Rate
8.99%
NOPAT
(85,436)
63,659
(81,867)
Net income
(86,057)
-205.69%
81,423
39.62%
58,318
246.57%
Dividends
(42,332)
(10,594)
Dividend yield
13.78%
2.94%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
243,162
138,222
87,484
Long-term debt
253,515
155,167
2,626
Deferred revenue
13,584
40
58
Other long-term liabilities
Net debt
400,121
229,760
(567,097)
Cash flow
Cash from operating activities
(2,349)
19,633
(6,939)
CAPEX
(139,169)
(223,519)
(252,205)
Cash from investing activities
(122,106)
(220,710)
(144,620)
Cash from financing activities
153,839
199,548
76,745
FCF
(240,261)
(197,431)
(237,548)
Balance
Cash
96,556
63,629
58,628
Long term investments
598,579
Excess cash
64,702
27,127
629,808
Stockholders' equity
460,288
589,101
507,734
Invested Capital
1,095,116
1,039,995
271,668
ROIC
9.71%
ROCE
6.55%
EV
Common stock shares outstanding
529,700
529,700
529,700
Price
0.58
-17.14%
0.70
2.94%
0.68
15.25%
Market cap
307,226
-17.14%
370,790
2.94%
360,196
15.25%
EV
707,248
600,912
(206,474)
EBITDA
(14,753)
102,147
(26,451)
EV/EBITDA
5.88
7.81
Interest
7,583
2,669
1,952
Interest/NOPBT
3.82%